NO20073367L - Makrolider - Google Patents

Makrolider

Info

Publication number
NO20073367L
NO20073367L NO20073367A NO20073367A NO20073367L NO 20073367 L NO20073367 L NO 20073367L NO 20073367 A NO20073367 A NO 20073367A NO 20073367 A NO20073367 A NO 20073367A NO 20073367 L NO20073367 L NO 20073367L
Authority
NO
Norway
Prior art keywords
compounds
methods
macrolides
intermediates
antibacterial
Prior art date
Application number
NO20073367A
Other languages
English (en)
Inventor
Thomas Victor Magee
Mark Edward Flanagan
Louis Stanley Chupak
Takushi Kaneko
Mark Carl Noe
Usa Reilly
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073367(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20073367L publication Critical patent/NO20073367L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Tires In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Makrolidforbindelser per se, som vist nedenfor og definert heri, og deres anvendelse, f.eks. som antibakterielle og antiprotozoale midler hos dyr, som inkluderer mennesker: Formel (I). Også beskrevet er fremgangsmåter for fremstilling av forbindelsene, intermediater og farmasøytiske sammensetninger derav, og fremgangsmåter for å behandle eller hindre sykdom ved å administrere forbindelsene til subjekter som trenger det.
NO20073367A 2004-12-21 2007-06-29 Makrolider NO20073367L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63809704P 2004-12-21 2004-12-21
US71753005P 2005-09-14 2005-09-14
PCT/IB2005/003829 WO2006067589A1 (en) 2004-12-21 2005-12-12 Macrolides

Publications (1)

Publication Number Publication Date
NO20073367L true NO20073367L (no) 2007-09-05

Family

ID=35809765

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073367A NO20073367L (no) 2004-12-21 2007-06-29 Makrolider

Country Status (35)

Country Link
US (1) US7462600B2 (no)
EP (2) EP1836211B1 (no)
JP (1) JP4111994B1 (no)
KR (1) KR100897678B1 (no)
CN (1) CN101120011A (no)
AP (1) AP2007004026A0 (no)
AR (1) AR052824A1 (no)
AT (1) ATE459633T1 (no)
AU (1) AU2005317735B2 (no)
BR (1) BRPI0519135A2 (no)
CA (1) CA2591746A1 (no)
CR (1) CR9202A (no)
DE (1) DE602005019786D1 (no)
DK (1) DK1836211T3 (no)
EA (1) EA011281B1 (no)
ES (1) ES2339871T3 (no)
GE (1) GEP20094834B (no)
GT (1) GT200500378A (no)
HN (1) HN2005036113A (no)
HR (1) HRP20100253T1 (no)
IL (1) IL183661A0 (no)
MA (1) MA29108B1 (no)
MX (1) MX2007007598A (no)
NL (1) NL1030713C2 (no)
NO (1) NO20073367L (no)
PE (1) PE20060948A1 (no)
PL (1) PL1836211T3 (no)
PT (1) PT1836211E (no)
SI (1) SI1836211T1 (no)
TN (1) TNSN07233A1 (no)
TW (1) TW200626608A (no)
UA (1) UA85937C2 (no)
UY (1) UY29285A1 (no)
WO (1) WO2006067589A1 (no)
ZA (1) ZA200705108B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
EP1928893A2 (en) 2005-08-24 2008-06-11 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
MX2009009074A (es) * 2007-03-13 2009-09-28 Pfizer Prod Inc Macrolidos basados en eritromicina.
US20100099674A1 (en) * 2007-03-21 2010-04-22 Innate Pharmaceuticals Ab Method and means for preventing and inhibiting type iii secretion in infections caused by gram-negative bacteria
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
AU2008340422B2 (en) 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011018510A1 (en) 2009-08-13 2011-02-17 Basilea Pharmaceutica Ag New macrolides and their use
HRP20160168T1 (hr) * 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
WO2012142125A2 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
CN102558047B (zh) * 2011-12-14 2013-10-30 天津药物研究院药业有限责任公司 3-甲基喹啉的制备方法
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
MX2015000362A (es) 2012-07-13 2015-04-14 Hoffmann La Roche Benzo(b)-azepin-2-onas antiproliferativas.
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN103739643A (zh) * 2013-12-30 2014-04-23 华东理工大学 利用分子印迹技术对红霉素进行回收分离纯化的方法
CN104230891B (zh) * 2014-08-27 2016-03-30 于宗光 一种托匹司他的制备方法
WO2018067663A2 (en) * 2016-10-04 2018-04-12 Biopharmati Sa Ketolides having antibacterial activity
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
CN111793022A (zh) * 2020-04-27 2020-10-20 滁州拜奥生物科技有限公司 一种3-甲基喹啉的制备方法
JP2025530768A (ja) * 2022-09-01 2025-09-17 ヘイガー バイオサイエンシズ，エルエルシー 神経疾患および精神疾患の治療のための、オレキシン受容体およびカッパオピオイド受容体に対する二重調節剤としてのピラゾール誘導体およびイミダゾール誘導体、組成物、ならびに治療法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US2823203A (en) 1954-06-24 1958-02-11 Abbott Lab Method of producing substantially pure erythromycin a
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US5075289A (en) 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5523399A (en) 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
FR2727969B1 (fr) 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5750510A (en) 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
EP0918783A1 (en) 1996-05-07 1999-06-02 Abbott Laboratories 6-o-substituted erythromycins and method for making them
FR2748746B1 (fr) 1996-05-14 1998-08-14 Hoechst Marion Roussel Inc Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
FR2751656B1 (fr) 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
DE69733439T2 (de) 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
US6191118B1 (en) * 1996-11-27 2001-02-20 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
AU6421398A (en) 1997-03-24 1998-10-20 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO1998051696A1 (en) 1997-05-09 1998-11-19 Pfizer Products Inc. Erythromycin derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US6034069A (en) 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
PA8461401A1 (es) 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
WO1999021869A1 (en) 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
DE69919769T2 (de) 1998-03-03 2005-01-27 Pfizer Products Inc., Groton 3,6-Ketal-Makrolidantibiotika
US5955440A (en) 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6248719B1 (en) 1998-06-03 2001-06-19 Pfizer Inc Tricyclic 3-keto derivatives of 6-O-methylerthromycin
JP4573925B2 (ja) 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
EE200100245A (et) 1998-11-03 2002-10-15 Pfizer Products Inc. Uued makroliidsed antibiootikumid
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
DK1147121T3 (da) 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US20020077302A1 (en) 1999-04-23 2002-06-20 Yong-Jin Wu Tricyclic erythromycin derivatives
US20020061857A1 (en) 1999-04-23 2002-05-23 Yong-Jin Wu 9-amino-3-oxo erythromycin derivatives
US6355620B1 (en) 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
EE200100613A (et) 1999-05-24 2003-02-17 Pfizer Products Inc. 13-metüülerütromütsiini derivaadid
JP2001072669A (ja) 1999-09-07 2001-03-21 Showa Kako Kk ７−クロロ−２，４（１ｈ，３ｈ）−キナゾリンジオンの製造方法
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
EP1114826A3 (en) 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1122261A3 (en) 2000-01-31 2001-09-26 Pfizer Products Inc. 13 and 14-membered antibacterial macrolides
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1146051A3 (en) 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020061856A1 (en) 2000-04-24 2002-05-23 Yong-Jin Wu Novel tricyclic erythromycin derivatives
EP1167376B1 (en) 2000-06-30 2004-07-14 Pfizer Products Inc. Macrolide antibiotics
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
JP2004531471A (ja) 2000-12-21 2004-10-14 グラクソ　グループ　リミテッド マクロライド抗生物質
US20020132782A1 (en) 2001-01-18 2002-09-19 Zhenkun Ma 9-amino erythromycin derivatives with antibacterial activity
WO2003004509A2 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US7022679B2 (en) 2002-05-13 2006-04-04 Enanta Pharmaceuticals, Inc. Processes for the preparation of 6-11 bicyclic erythromycin derivatives
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
MXPA05011276A (es) 2003-04-21 2006-01-24 Daiichi Seiyaku Co Derivado heterociclico de cinco miembros.
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
WO2006046112A2 (en) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
GB0424951D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
TW200635600A (en) 2004-12-13 2006-10-16 Enanta Pharm Inc Tetracyclic bicyclolides
US7291602B2 (en) 2004-12-13 2007-11-06 Enanta Pharmaceuticals, Inc. 11,12-lactone bicyclolides

Also Published As

Publication number Publication date
NL1030713A1 (nl) 2006-06-22
MX2007007598A (es) 2007-07-25
EP1836211B1 (en) 2010-03-03
ZA200705108B (en) 2009-01-28
JP4111994B1 (ja) 2008-07-02
JP2008524319A (ja) 2008-07-10
AP2007004026A0 (en) 2007-06-30
CA2591746A1 (en) 2006-06-29
HN2005036113A (es) 2010-12-06
MA29108B1 (fr) 2007-12-03
AU2005317735B2 (en) 2009-06-04
UY29285A1 (es) 2006-07-31
CR9202A (es) 2007-07-16
TNSN07233A1 (fr) 2008-11-21
KR100897678B1 (ko) 2009-05-14
PE20060948A1 (es) 2006-10-11
US20060135447A1 (en) 2006-06-22
CN101120011A (zh) 2008-02-06
EA011281B1 (ru) 2009-02-27
AR052824A1 (es) 2007-04-04
HRP20100253T1 (hr) 2010-06-30
IL183661A0 (en) 2007-09-20
ATE459633T1 (de) 2010-03-15
EP1836211A1 (en) 2007-09-26
EA200701113A1 (ru) 2007-12-28
DE602005019786D1 (de) 2010-04-15
NL1030713C2 (nl) 2006-12-12
ES2339871T3 (es) 2010-05-26
PT1836211E (pt) 2010-04-08
UA85937C2 (uk) 2009-03-10
BRPI0519135A2 (pt) 2008-12-23
KR20070089191A (ko) 2007-08-30
PL1836211T3 (pl) 2010-07-30
TW200626608A (en) 2006-08-01
EP2233493A1 (en) 2010-09-29
US7462600B2 (en) 2008-12-09
WO2006067589A1 (en) 2006-06-29
SI1836211T1 (sl) 2010-04-30
DK1836211T3 (da) 2010-05-17
AU2005317735A1 (en) 2006-06-29
GT200500378A (es) 2006-11-28
GEP20094834B (en) 2009-11-25

Similar Documents

Publication Publication Date Title
NO20082709L (no) Kjemiske forbindelser
NO20073719L (no) Kjemiske forbindelser
TW200626608A (en) Macrolides
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20074703L (no) Antibakterielle piperidinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20081844L (no) Terapeutiske forbindelser
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
NO20091605L (no) Pyridinonforbindelser
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
NO20061743L (no) Kinazolinderivater
NO20091683L (no) Kjemiske forbindelser
WO2007135527A3 (en) Benzimidazolyl compounds
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20063449L (no) Substituerte heterocykler og deres anvendelse
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application